| Name
|
Glucagon (19-29), Human
|
| Other Name
|
|
| Sequence (Single letter abbreviations)
|
AQDFVQWLMNT
|
| Sequence（Three letter abbreviations）
|
{ALA}{GLN}{ASP}{PHE}{VAL}{GLN}{TRP}{LEU}{MET}{ASN}{THR}
|
| Basic description
|
Glucagon is a 29-amino-acid peptide hormone liberated in the alpha cells of the islets of Langerhans. Glucagon-producing alpha cells represent one of the earliest populations of detectable islet cells in the developing endocrine pancreas. Glucagon is generally viewed as a hormone that opposes the action of insulin in peripheral tissues, predominantly the liver, where the insulin:glucagon ratio determines the intricate control of gluconeogenesis and glycogenolysis. The action of glucagon in the liver is complex and involves coordinate regulation of transcription factors and signal transduction networks which converge on regulation of amino acid, lipid and carbohydrate metabolism.
|
| Solubility
|
This peptide is soluble in water. The contents of this vial have been accurately determined. Both the stopper and the vial have been siliconized. Do not attempt to weigh out a smaller portion of the contents.
|
| The molecular weight
|
1352.520
|
| Chemical formula
|
C61H89N15O18S1
|
| The purity
|
> 95%
|
| Storage conditions
|
Store the peptide at -20°C.
|
| Annotation
|
|
| Documents
|
|
| Figures
|
|
| Reference
|
Vessey KA, et al. Glucagon- and secretin-related peptides differentially alter ocular growth and the development of form-deprivation myopia in chicks. Invest Ophthalmol Vis Sci. Nov 2005; 46(11): 3932-3942.
Fontes G, et al. Miniglucagon (MG)-generating endopeptidase, which processes glucagon into MG, is composed of N-arginine dibasic convertase and aminopeptidase B. Endocrinology. Feb 2005; 146(2): 702-712.
|
Glucagon (19-29), Human
